Bharat Biotech, Ocugen reach pact on CovaxinAs per the deal, Ocugen and Bharat Biotech would share the profits from Covaxin sale in the US
Last Updated IST
Credit: DH.
Ocugen Inc and Bharat Biotech have announced “a definitive agreement” to co-develop, supply, and commercialise Covaxin for the United States market.
As per the deal, Ocugen and Bharat Biotech would share the profits from Covaxin sale in the US, in a 45:55 ratio. Ocugen is in active discussions with manufacturers in the US to produce a significant number of Covaxin doses to support its US immunisation programme.
The business intent between the Pennsylvania and Hyderabad based firms was announced in December.